Attachment 1. Product Information for cobicistat

‘Erectile dysfunction and statin treatment in high cardiovascular risk patients.’ ... The published rates for the comparable outcome of "adverse events leading to discontinuation” in METEOR are 11% rosuvastatin vs 8% placebo (see JAMA 2007; 297: 1344-53 in Supporting Material).Note: If, on the other hand, it was intended that rates of all ... ................
................